Experience with a six-month regimen of Pneumocystis pneumonia prophylaxis in 122 HIV-positive kidney transplant recipients

Keyphrases

• Kidney Transplant Recipients 100%
• HIV-positive 100%
• Pneumocystis Pneumonia Prophylaxis 100%
• HIV-positive Recipient 100%
• Pneumocystis Jirovecii 66%
• CD4 Count 33%
• HIV Infection 33%
• Tacrolimus 33%
• Cyclosporine 33%
• HIV-negative 33%
• Calcineurin Inhibitors 33%
• University Hospital 33%
• Trimethoprim-sulfamethoxazole (TMP-SMX) 33%
• Antiproliferative Activity 33%
• Prednisone 33%
• Kidney Transplant 33%
• Sirolimus 33%
• Intravenous Immunoglobulin (IVIg) 33%
• Hahnemann 33%
• Antithymocyte Globulin 33%
• Maintenance Immunosuppression 33%
• Primary Prophylaxis 33%
• Mycophenolate 33%
• IL-2 Receptor Antagonist 33%
• Alternative Agents 33%
• Induction Immunosuppression 33%

Medicine and Dentistry

• Kidney Graft 100%
• Human Immunodeficiency Virus 100%
• Pneumocystis Pneumonia 100%
• Transplantation 50%
• Immunosuppressive Treatment 33%
• Cyclosporine 16%
• Human Immunodeficiency Virus Infection 16%
• Prednisone 16%
• Trimethoprim/Sulfamethoxazole 16%
• Cell Count 16%
• Immunoglobulin 16%
• Tacrolimus 16%
• Rapamycin 16%
• Receptor Antagonist 16%
• Calcineurin Inhibitor 16%
• Thymocyte Antibody 16%
• Mycophenolic Acid 16%

Pharmacology, Toxicology and Pharmaceutical Science

• HIV 100%
• Pneumocystis Pneumonia 100%
• Tacrolimus 16%
• Human Immunodeficiency Virus Infection 16%
• Receptor Antagonist 16%
• Prednisone 16%
• Cotrimoxazole 16%
• Rapamycin 16%
• Immunoglobulin 16%
• Mycophenolic Acid 16%
• Ciclosporin 16%
• Thymocyte Antibody 16%
• Calcineurin Inhibitor 16%